McLoughlin, C., Roberts, T.E., Jackson, L.J. et al. (17 more authors) (2019) Cost-effectiveness of cell salvage and donor blood transfusion during caesarean section: results from a randomised controlled trial. BMJ Open, 9. e022352. ISSN 2044-6055
Abstract
Objectives To evaluate the cost-effectiveness of routine use of cell salvage during caesarean section in mothers at risk of haemorrhage compared with current standard of care.Design Model-based cost-effectiveness evaluation alongside a multicentre randomised controlled trial. Three main analyses were carried out on the trial data: (1) based on the intention-to-treat principle; (2) based on the per-protocol principle; (3) only participants who underwent an emergency caesarean section.Setting 26 obstetric units in the UK.Participants 3028 women at risk of haemorrhage recruited between June 2013 and April 2016.Interventions Cell salvage (intervention) versus routine care without salvage (control).Primary outcome measures Cost-effectiveness based on incremental cost per donor blood transfusion avoided.Results In the intention-to-treat analysis, the mean difference in total costs between cell salvage and standard care was £83. The estimated incremental cost-effectiveness ratio (ICER) was £8110 per donor blood transfusion avoided. For the per-protocol analysis, the mean difference in total costs was £92 and the ICER was £8252. In the emergency caesarean section analysis, the mean difference in total costs was £55 and the ICER was £13 713 per donor blood transfusion avoided. This ICER is driven by the increased probability that these patients would require a higher level of postoperative care and additional surgeries. The results of these analyses were shown to be robust for the majority of deterministic sensitivity analyses.Conclusions The results of the economic evaluation suggest that while routine cell salvage is a marginally more effective strategy than standard care in avoiding a donor blood transfusion, there is uncertainty in relation to whether it is a less or more costly strategy. The lack of long-term data on the health and quality of life of patients in both arms of the trial means that further research is needed to fully understand the cost implications of both strategies.Trial registration number ISRCTN66118656.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > ScHARR - Sheffield Centre for Health and Related Research |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 08 Mar 2019 16:07 |
Last Modified: | 10 Mar 2019 03:46 |
Published Version: | https://doi.org/10.1136/bmjopen-2018-022352 |
Status: | Published |
Publisher: | British Medical Journal Publishing Group |
Refereed: | Yes |
Identification Number: | 10.1136/bmjopen-2018-022352 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:142759 |
Download
Filename: cost effectiveness of cell salvage and donor blood.pdf
Licence: CC-BY 4.0